Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
Primary Purpose
Acute Lymphoblastic Leukemia
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
AYA ADAPTS (ADherence Assessments and Personalized Timely Support).
Sponsored by
About this trial
This is an interventional supportive care trial for Acute Lymphoblastic Leukemia focused on measuring Adherence, Adolescent, Young Adult, Mobile Health, Oncology
Eligibility Criteria
Inclusion Criteria:
- Ages 15-25
- Diagnosed with acute lymphoblastic leukemia (ALL)
- In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining
- Prescribed 6-mercaptopurine (6MP)
- Self-reported 6MP adherence <95% in the past month
- English language proficiency
- For AYA <18, must have informed consent from their caregiver.
Exclusion Criteria:
- Cognitive impairments that would limit ability to complete measures, determined by the medical team
- Absence of inclusion criteria above.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Contextually-tailored Mobile Messages for Adherence
No messages
Arm Description
All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
Outcomes
Primary Outcome Measures
Screening Rate
Number of AYA patients referred and screened per month
Recruitment Rate
Number of AYA patients enrolled in the study per month
Retention Rate
Number of AYA subjects who complete the intervention, out of the total number of AYA subjects enrolled in the study
Intervention Engagement
Number of acknowledged micro-randomized text messages; categorized by "thumbs up", "thumbs down", and "snooze" responses
Technical Difficulties
Number of technical glitches and errors experienced in implementing the intervention
Intervention Satisfaction
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Intervention Perceived Appropriateness
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Intervention Perceived Positive Effects
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Intervention Perceived Demands
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Potential for Intervention Future Use
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03932903
Brief Title
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
Official Title
Using Real Time Mobile Health Approaches to Understand and Promote Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.
Detailed Description
This is a 28-day micro-randomized pilot trial (i.e., a sequential factorial design) of a just-in-time adaptive intervention (JITAI) called AYA ADAPTS (ADherence Assessments and Personalized Timely Support). AYA ADAPTS is an app that integrate contextually-tailored mobile messages designed to promote oral chemotherapy adherence. Participants in the study will electronically-monitor 6MP adherence with MEMS TrackCaps and complete short ecological momentary assessment (EMA) surveys each afternoon, at the same time prior to the evening 6MP dose, for the 28-day period.
AYA ADAPTS will deliver contextually-tailored text messages triggered based on EMA responses (e.g., based on fatigue, mood) and objective data (e.g., time of day, weekend vs. weekday). After receiving a contextually-tailored message, AYA will be asked to acknowledge receipt of the message by pressing a "thumbs up" or "thumbs down" button, to indicate whether or not they liked the message, or a "snooze" button indicating that it was not a good time to receive the message.
Following the 28-day intervention period, MEMS TrackCaps will be returned and downloaded during the clinic appointment. AYA will complete a brief acceptability survey electronically via REDCAP, rating AYA ADAPTS on a 5-point Likert scale to assess satisfaction, perceived appropriateness, perceive positive effects, perceived demands, and potential for future use. Exit interviews will also be conducted, audio-recorded, and transcribed to further assess acceptability. For feasibility, the following variables will be tracked: (1) screening rates, (2) recruitment rates, (3) % acknowledged micro-randomized messages, (4) technical difficulties (e.g., micro-randomized messages received when intended), (5) retention rates, and (6) completed assessments (EMA, MEMS, post-measures).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lymphoblastic Leukemia
Keywords
Adherence, Adolescent, Young Adult, Mobile Health, Oncology
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a 28-day micro-randomized pilot trial (i.e., a sequential factorial design) of a just-in-time adaptive intervention called AYA ADAPTS (Adherence Assessments and Personalized Timely Support). AYA ADAPTS is an app that will deliver contextually-tailored mobile messages (adapted to AYA's current states, such as mood, pain, and location) designed to promote oral chemotherapy adherence. Each AYA in the study (n=30) will be micro-randomized (with a 60% probability) to receive a contextually-tailored message each day that supports abilities to self-manage and maintain adherence, delivered prior to their scheduled dose, over a 28-day period (i.e., the period between follow-up appointments). The remaining 40% of days, participants will be assigned to receive no messages (i.e., no intervention).
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Contextually-tailored Mobile Messages for Adherence
Arm Type
Experimental
Arm Description
All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
Arm Title
No messages
Arm Type
No Intervention
Arm Description
All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
Intervention Type
Behavioral
Intervention Name(s)
AYA ADAPTS (ADherence Assessments and Personalized Timely Support).
Intervention Description
AYA ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in adolescents and young adults with acute lymphoblastic leukemia. Each participant will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days.
Primary Outcome Measure Information:
Title
Screening Rate
Description
Number of AYA patients referred and screened per month
Time Frame
Up to 12 months
Title
Recruitment Rate
Description
Number of AYA patients enrolled in the study per month
Time Frame
Up to 12 months
Title
Retention Rate
Description
Number of AYA subjects who complete the intervention, out of the total number of AYA subjects enrolled in the study
Time Frame
Up to 12 months
Title
Intervention Engagement
Description
Number of acknowledged micro-randomized text messages; categorized by "thumbs up", "thumbs down", and "snooze" responses
Time Frame
28-day intervention period
Title
Technical Difficulties
Description
Number of technical glitches and errors experienced in implementing the intervention
Time Frame
28-day intervention period
Title
Intervention Satisfaction
Description
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Time Frame
At completion of 28-day intervention
Title
Intervention Perceived Appropriateness
Description
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Time Frame
At completion of 28-day intervention
Title
Intervention Perceived Positive Effects
Description
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Time Frame
At completion of 28-day intervention
Title
Intervention Perceived Demands
Description
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Time Frame
At completion of 28-day intervention
Title
Potential for Intervention Future Use
Description
5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely)
Time Frame
At completion of 28-day intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ages 14-25
Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma
In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining
Prescribed 6-mercaptopurine (6MP)
English language proficiency
For AYA <18, must have informed consent from their caregiver.
Exclusion Criteria:
Cognitive impairments that would limit ability to complete measures, determined by the medical team
Absence of inclusion criteria above.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra M Psihogios, Ph.D.
Phone
240-994-6546
Email
alex.psihogios@northwestern.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra M Psihogios, Ph.D.
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
24829202
Citation
Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, Evans WE, Bostrom B, Casillas J, Dickens DS, Maloney KW, Neglia JP, Ravindranath Y, Ritchey AK, Wong FL, Relling MV. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2014 Oct 9;124(15):2345-53. doi: 10.1182/blood-2014-01-552166. Epub 2014 May 14.
Results Reference
background
PubMed Identifier
22218838
Citation
Modi AC, Pai AL, Hommel KA, Hood KK, Cortina S, Hilliard ME, Guilfoyle SM, Gray WN, Drotar D. Pediatric self-management: a framework for research, practice, and policy. Pediatrics. 2012 Feb;129(2):e473-85. doi: 10.1542/peds.2011-1635. Epub 2012 Jan 4.
Results Reference
background
PubMed Identifier
26651463
Citation
Klasnja P, Hekler EB, Shiffman S, Boruvka A, Almirall D, Tewari A, Murphy SA. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015 Dec;34S(0):1220-8. doi: 10.1037/hea0000305.
Results Reference
background
PubMed Identifier
27663578
Citation
Nahum-Shani I, Smith SN, Spring BJ, Collins LM, Witkiewitz K, Tewari A, Murphy SA. Just-in-Time Adaptive Interventions (JITAIs) in Mobile Health: Key Components and Design Principles for Ongoing Health Behavior Support. Ann Behav Med. 2018 May 18;52(6):446-462. doi: 10.1007/s12160-016-9830-8.
Results Reference
background
PubMed Identifier
30998225
Citation
Psihogios AM, Li Y, Butler E, Hamilton J, Daniel LC, Barakat LP, Bonafide CP, Schwartz LA. Text Message Responsivity in a 2-Way Short Message Service Pilot Intervention With Adolescent and Young Adult Survivors of Cancer. JMIR Mhealth Uhealth. 2019 Apr 18;7(4):e12547. doi: 10.2196/12547.
Results Reference
background
PubMed Identifier
29982694
Citation
Psihogios AM, Fellmeth H, Schwartz LA, Barakat LP. Family Functioning and Medical Adherence Across Children and Adolescents With Chronic Health Conditions: A Meta-Analysis. J Pediatr Psychol. 2019 Jan 1;44(1):84-97. doi: 10.1093/jpepsy/jsy044.
Results Reference
background
PubMed Identifier
26372619
Citation
McGrady ME, Brown GA, Pai AL. Medication adherence decision-making among adolescents and young adults with cancer. Eur J Oncol Nurs. 2016 Feb;20:207-14. doi: 10.1016/j.ejon.2015.08.007. Epub 2015 Sep 12.
Results Reference
background
PubMed Identifier
20212260
Citation
Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010 Nov 10;28(32):4800-9. doi: 10.1200/JCO.2009.22.2802. Epub 2010 Mar 8.
Results Reference
background
Learn more about this trial
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
We'll reach out to this number within 24 hrs